Targets › GDF15
4 programs from 4 companies in 9 trials: 5 Phase 2, 4 Phase 1; Oncology, Other; next expected readout Dec 2026.
Hormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. (UniProt, Q99988)
Open in Phaseline: the race on GDF15, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | ponsegromab GDF15 neutralizing monoclonal antibody | GDF15 | Phase 2 | Cachexia | Jan 2028 |
| CatalYm | Visugromab (CTL-002) GDF-15 neutralizing antibody | GDF15 | Phase 2 | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Unresectable or Metastatic Hepatocellular Carcinoma; Cancer-associated Cachexia; Solid Tumor, Adult | Apr 2028 |
| AVEO Pharmaceuticals | AV-380 anti-GDF-15 monoclonal antibody | GDF15 | Phase 1 | Cachexia | Dec 2026 |
| Kexing Biopharm | GB18 GDF15 monoclonal antibody antagonist | GDF15 | Phase 1 | Cachexia; Cancer; Cancer Cachexia (CC) | Sep 2027 |
Metastatic Non-Squamous Non-Small Cell Lung Cancer (2) Cachexia (2) Unresectable or Metastatic Hepatocellular Carcinoma (1) Cancer-associated Cachexia (1) Solid Tumor, Adult (1) Cachexia; Cancer (1) Cancer Cachexia (CC) (1)
antibody (2), small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.